Jubilant Pharmova announces completion of USFDA audit of Radiopharmaceuticals manufacturing facility at Montreal

The USFDA has issued 5 observations pursuant to the completion of audit

Ablaze and Yonghe Pharma initiate development and manufacturing agreement for targeted radiopharmaceutical therapies

Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze

Jubilant receives EIR from USFDA for its radiopharmaceuticals manufacturing facility Montreal Canada

With the receipt of the EIR, the inspection stands successfully closed.

SOFIE Biosciences doses first patient in Phase 3 trial of novel cancer imaging agent

The study will run across 18 sites and enroll roughly 200 patients over 24 months

Harbour BioMed teams up with Lannacheng to advance next-generation cancer therapies

Harbour BioMed brings advanced antibody discovery platforms to the table

SK Biopharmaceuticals acquires exclusive global rights for WARF cancer drug candidate

GAIASO appoints Dr. Tracey Brown as CEO

Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,

Jubilant Draximage to invest US$ 50 million to expand its PET radiopharmacy network

Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network

Novartis to acquire Mariana Oncology for upfront US$ 1 billion

Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications

AstraZeneca buys biopharmaceutical company Fusion

To accelerate the development of next-generation radioconjugates to treat cancer